Molecular pathways: Extracting medical knowledge from high-throughput genomic data

Clinical Cancer Research

Volumn 19, Issue 12, 2013, Pages 3114-3120

  Goldstein, Theodore C ^a   Paull, Evan O ^a   Ellis, Matthew J ^b,c   Stuart, Joshua M ^a  

^a University of California Santa Cruz   (United States)

^b Division of Oncology   (United States)

^c Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RNA;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PROGNOSIS; CANCER RESEARCH; DRUG RESPONSE; DRUG TARGETING; EPIGENETICS; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENOME ANALYSIS; GENOMICS; HIGH RISK PATIENT; HIGH THROUGHPUT GENOMICS; HUMAN; INFORMATION PROCESSING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MUTATION; NEOPLASMS; PATHOLOGY, MOLECULAR; RNA, MESSENGER;

EID: 84879469711     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2093     Document Type: Article

References (11)

1. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2012;109:2724-9.
2. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010;26:i237-45.
3. Kschischang FR, Frey BJ, Loeliger HA. Factor graphs and the sumproduct algorithm. IEEE Transactions on Information Theory 2001;47: 498-519.
4. Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 2011;18:507-22.
5. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012;22:398-406.
6. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
7. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
8. Chen R, Li L, Butte AJ. AILUN: reannotating gene expression data automatically. Nat Methods 2007;4:879.
9. Huang H, Liu CC, Zhou XJ. Bayesian approach to transforming public gene expression repositories into disease diagnosis databases. Proc Natl Acad Sci U S A 2010;107:6823-8.
10. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
11. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011;29: 2342-9.